Drug · CHEMBL558
MEXILETINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MEXILETINE. Drugs and targets, record CHEMBL558. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL558
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials31
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02260388 | Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations | Phase 4 | 402 | 2018-07-06 | mexiletine | Its name | ClinicalTrials.gov |
| NCT01849770 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS) | Phase 2 | 75 | 2015-10-12 | mexiletine | Its name | ClinicalTrials.gov |
| NCT00832000 | Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia | Phase 2 | 59 | 2013-03-11 | mexiletine | Its name | ClinicalTrials.gov |
| NCT01406873 | Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 | Phase 2 | 42 | 2018-03-29 | mexiletine | Its name | ClinicalTrials.gov |
| NCT01811355 | Mexiletine for the Treatment of Muscle Cramps in ALS | Phase 4 | 23 | 2017-06-27 | mexiletine | Its name | ClinicalTrials.gov |
| NCT02308748 | Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block | Phase 1 | 22 | 2016-06-08 | mexiletine | Its name | ClinicalTrials.gov |
| NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | Phase 2 | 20 | 2019-12-05 | mexiletine | Its name | ClinicalTrials.gov |
| NCT02561702 | Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease | Phase 2 | 4 | 2018-03-26 | mexiletine | Its name | ClinicalTrials.gov |
| NCT00905853 | Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy | Phase 4 | 260 | mexiletine | Its name | ClinicalTrials.gov | |
| NCT00000793 | A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection | Phase 2 | 240 | mexiletine | Its name | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Mexiletine Treatment vs Placebo Treatment: serious adverse events | 1 of 57 | 0 of 57 | 114 | NCT00832000 | Trial comparisons |
| Mexiletine vs Placebo: deaths from any cause | 0 of 23 | 0 of 21 | 44 | NCT01811355 | Trial comparisons |
| Mexiletine vs Placebo: serious adverse events | 0 of 23 | 0 of 21 | 44 | NCT01811355 | Trial comparisons |
| Mexiletine vs Placebo: deaths from any cause | 0 of 21 | 0 of 21 | 42 | NCT01406873 | Trial comparisons |
| Mexiletine vs Placebo: serious adverse events | 1 of 21 | 1 of 21 | 42 | NCT01406873 | Trial comparisons |
| Mexiletine vs Placebo: Number of Participants With a Decrease in Cramp Intensity | 1 of 4 | 2 of 4 | 8 | NCT02561702 | Trial comparisons |
| Mexiletine vs Placebo: Number of Participants With a Decrease in Cramp Duration | 2 of 4 | 0 of 4 | 8 | NCT02561702 | Trial comparisons |
| Mexiletine vs Placebo: deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT02561702 | Trial comparisons |
| Mexiletine vs Placebo: serious adverse events | 0 of 4 | 0 of 4 | 8 | NCT02561702 | Trial comparisons |
Papers from its trials17
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL558
GET https://conductscience.org/api/drugs/v1/CHEMBL558/trials?page=2